New
Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Advertisement
Advertisement
CANCvsETF 2ETF Comparison
Choose a second ETF to run a side-by-side ETF comparison with CANC, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
CANC performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 03/12/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CANC ETF 2 | -0.94%– | +4.18%– | +4.10%– | +43.76%– | n/a– | n/a– |
| Flows | CANC ETF 2 | +$12M– | +$49M– | +$41M– | +$63M– | -– | -– |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CANC ETF 2 | +23.29%– | +25.13%– | n/a– | n/a– |
| Max drawdown | CANC ETF 2 | -4.68%– | -17.26%– | n/a– | n/a– |
| Max drawdown duration | CANC ETF 2 | 16d– | 80d– | n/a– | n/a– |
Trading data
CANC | ETF 2 | |
Last sale 3/13/2026 at 1:30 PM | $36.15 | – |
| Previous close 03/12/2026 | $36.33 | – |
| Consolidated volume 03/12/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Advertisement
Main metrics
Last update 3/13/2026 at 1:30 PM
Live
Closed
CANC | ETF 2 | |
|---|---|---|
| Last price | $36.15 | – |
| 1D performance | -0.50% | – |
| AuM | $161.18 M | – |
| E/R | 0.99% | – |
Characteristics
CANC | ETF 2 | |
|---|---|---|
| Management strategy | Active | – |
| Provider | Tema | – |
| Benchmark | - | – |
| N° of holdings | 46 | – |
| Asset class | - | – |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 15, 2023 | – |
| ESG | No | – |
Advertisement
Exposure
Countries
CANC
USA
88.08%
Other
11.92%
ETF 2
Sectors
CANC
Health Care
80.79%
Other
19.21%
ETF 2
Advertisement
Diversification
CANC
Total weight of top 15 holdings out of 15
56.2%
ETF 2
–
Top 15 holdings
Data as of January 31, 2026
CANC
REVOLUTION MEDICINES INC
6.31%
BRIDGEBIO PHARMA
4.61%
NOVARTIS
4.56%
ASTRAZENECA
4.33%
US7711951043
4.14%
LILLY
3.94%
BRISTOL-MYERS SQUIBB
3.89%
US3723032062
3.68%
MERCK & CO INC
3.49%
COGENT BIOSCIENCES
3.42%
NUVALENT
3.25%
IMMUNOME
2.96%
CELCUITY INC
2.67%
AMGEN-T
2.51%
JOHNSON&JOHNSON
2.44%
ETF 2
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
Advertisement
Advertisement
Advertisement
Webcast on Demand
Calamos Investments Powers the Next Phase of the Autocallable Revolution
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
